KDOQI (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471–530 National ...

leading to potential misinterpretations of a patient's glycemic control and subsequent treatment decisions. Recent studies have focused on the analytical challenges posed by various hemoglobin ...

IN 1955 Rucknagel et al. 1 described a new abnormal hemoglobin in a Negro family in North Carolina. This hemoglobin, designated "I", migrated more rapidly than normal hemoglobin on filter-paper ...

Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...

We investigate these dynamics for a food-as-medicine program to treat diabetes, where eligibility required elevated hemoglobin A1c (HbA1c). Both treatment and control groups experienced significant ...

The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...

MTL-HBG is an RNAa medicine designed to increase transcription of the gamma globin gene (HBG), enabling people with sickle cell disease to produce enhanced levels of fetal hemoglobin (HbF).